select search filters
briefings
roundups & rapid reactions
before the headlines
Fiona fox's blog
Migraines are a highly prevalent condition and are among the leading causes of disability worldwide. Numerous oral drugs with different mechanisms of action are available for the acute management of migraine attacks, but there is no clear consensus among clinical guidelines about the ranking of these treatments. Previous systematic reviews and network meta-analyses have only included a subset of currently licensed drugs.
This new study, which will be published next Wednesday in the BMJ, is a systematic review and network meta-analysis which has compared all licensed drugs for the acute treatment of migraine attacks in adults.
Researchers included 137 RCTs, comprising 89,445 participants allocated to one of 17 active interventions or a placebo.
Journalists came to this SMC briefing to hear from the authors and ask their questions.
Speakers included:
Professor Andrea Cipriani, Professor of Psychiatry, University of Oxford and Director of the Oxford Health Clinical Research Facility
Professor Messoud Ashina, Professor of Neurology, University of Copenhagen
Elena Ruiz de la Torre, Executive Director, European Migraine & Headache Alliance, Belgium